Nova Eye Medical Files IDE Application with the FDA to Commence a Pivotal Study in the US Evaluating 2RT
ASX Announcement AlphaRET
5 Jul, 2021
2RT® Featured at the 2021 Meeting of the Association for Research in Vision and Ophthalmology
ASX Announcement General AlphaRET
3 May, 2021
Five-Year Post-LEAD Review Shows Improvement in 2RT® Treatment Benefits for iAMD
ASX Announcement General AlphaRET
5 Mar, 2021
Nova Eye Medical Establishes AlphaRET to Support Commercial Development of 2RT®
ASX Announcement AlphaRET
26 Oct, 2020
For investor enquires please contact:
Dr. Tom Duthy
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com
This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More
The cookies do not store any personalised information. Learn More